Investigational drug · Phase 2
YZJ-4729
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pain.
Phase 2Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "YZJ-4729"
First trial start
2025
May 23, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YZJ-4729", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pain
Approved drugs for the same conditions: Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "YZJ-4729" as an intervention, largest first.
- A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal SurgeryPivotal-lookingActive, not recruiting
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
NCT06890533 · 560 participants (planned) · Start May 14, 2025 · Primary completion Apr 17, 2026
Drug: Experimental: YZJ-4729; Placebo Comparator: Saline and 1 more · For: Pain
Sites: Cangzhou, China; Changde, China; Changsha, China · 49 sites in all
- A Phase Ⅱ Study to Evaluate the Efficacy and Safety of YZJ-4729 in Patients With Moderate to Severe Acute Pain After Abdominal SurgeryPivotal-lookingCompleted
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
NCT06680466 · 179 participants · Start Dec 26, 2023 · Primary completion Jul 15, 2024
Drug: YZJ-4729; morphine and 4 more · For: Pain
Sites: Changsha, China
- A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Orthopedic SurgeryPivotal-lookingCompleted
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
NCT06901830 · 150 participants · Start May 23, 2025 · Primary completion Dec 6, 2025
Drug: YZJ-4729; Placebo Comparator: Saline and 1 more · For: Pain
Sites: Changsha, China; Chengdu, China; Ch’ang-ch’un, China · 21 sites in all
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.Industry
NCT06681493 · 66 participants · Start Oct 12, 2022 · Primary completion Apr 14, 2023
Drug: YZJ-4729 Tartrate injection; YZJ-4729 simulated injection · For: Postoperative Analgesia
Sites: Changsha, China
Newest research
PubMed records naming it or its code names, newest first.
- Development and validation of an LC-MS/MS method for quantifying a new G protein selective μ-opioid receptor agonist YZJ-4729 and its major metabolite M10 in human plasma to support a phase I study in healthy subjects.
Ni Y, Ding C, Cheng M, et al. · J Chromatogr B Analyt Technol Biomed Life Sci 2025
- Pharmacokinetics, metabolite profiling, safety and tolerability of YZJ-4729 tartrate, a novel G protein-biased μ-opioid receptor agonist, in healthy Chinese subjects.
Ni Y, Gao H, Ouyang W, et al. · Front Pharmacol 2023
Also in development for Pain
- CebranopadolTRN-228Phase 34 trials
Adneuris Therapeutics, Inc. · Pain, Acute Pain, Chronic Pain
- Active Comparator: MorphinePhase 32 trials
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Pain
- CT001Phase 31 trial
Cessatech A/S · Pain
- MR-107A-02Phase 31 trial
Viatris Specialty LLC · Acute Pain, Post Operative Pain, Pain
- SRP-001Phase 21 trial
South Rampart Pharma, Inc. · Acute Pain, Postoperative Pain, Pain
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.